People: Quidel Corp (QDEL.O)

Summary

Name	Age	Since	Current Position
Mark Pulido	60	2004	Independent Chairman of the Board
Douglas Bryant	55	2009	President, Chief Executive Officer, Director
Randall Steward	58	2011	Chief Financial Officer
Robert Bujarski	44	2010	Senior Vice President - Business Development, General Counsel, Corporate Secretary
Scot McLeod	48	2007	Senior Vice President - Operations
Mark Smits	55	2011	Senior Vice President - Commercial Operations
John Tamerius	67	2008	Senior Vice President - Clinical, Regulatory Affairs
Timothy Stenzel	51	2009	Chief Scientific Officer
Thomas Brown	65	2004	Independent Director
Kenneth Buechler	59	2007	Independent Director
Rodney Dammeyer	72	2006	Independent Director
Mary Polan	69	1993	Independent Director
Jack Schuler	72	2006	Independent Director

» Insider Trading

Biographies

Name	Description
Mark Pulido	Mr. Mark A. Pulido is Independent Chairman of the Board of Quidel Corporation. He was appointed to Board of Directors in August 2002. Mr. Pulido has been Chairman of the Company’s Board of Directors since May 2004. Prior to his retirement in June 2002, Mr. Pulido served as the Chairman of the Board of BenefitPoint, Inc., an employee benefits technology company, where he also served as its President and Chief Executive Officer. From May 1996 to July 1999, Mr. Pulido was President and Chief Executive Officer of McKesson Corporation, a healthcare services and information technology company. Previously, Mr. Pulido served as President and Chief Executive Officer of Novartis Pharmaceuticals Corporation (formerly Sandoz Pharmaceuticals Corporation), a research-based pharmaceutical manufacturer, and RedLine Healthcare Corporation (previously owned by Novartis and now a subsidiary of McKesson Corp.), a medical surgical distribution company, during the period from January 1990 to April 1996. Mr. Pulido is currently an affiliated executive with Freeman Spogli, a private equity firm, and serves on the Board of Directors of BHC, an industrial products distribution company and a Freeman Spogli portfolio company, and ABILITY Network Inc., a healthcare information technology company. Mr. Pulido holds a B.S. degree in Pharmacy from the University of Arizona, College of Pharmacy, and an M.S. degree in Pharmacy Administration from the University of Minnesota.
Douglas Bryant	Mr. Douglas C. Bryant is President, Chief Executive Officer, Director of Quidel Corporation. He was appointed to the Board of Directors on February 2, 2009 and became President and Chief Executive Officer on March 1, 2009. Prior to joining the Company, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, Mr. Bryant held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations Asia Pacific. Mr. Bryant has about 30 years of industry experience in sales and marketing, product development, manufacturing and service and support in both the diagnostics and life sciences markets. Mr. Bryant holds a B.A. in Economics from the University of California at Davis.
Randall Steward	Mr. Randall J. Steward is Chief Financial Officer of Quidel Corporation, since October 31, 2011. Prior to joining the Company, Mr. Steward served as the Chief Financial Officer for Navilyst Medical, Inc, a medical device company based in Massachusetts. From 2008 to January 2011, Mr. Steward served as Chief Operating Officer for SeQual Technologies, Inc., a San Diego-based medical device company, where he was responsible for all aspects of engineering, manufacturing, finance, and information systems. Prior to SeQual Technologies, Mr. Steward spent 11 years with Spectrum Brands as Executive Vice President and Chief Financial Officer. Mr. Steward holds a B.B.A. in Accounting from Southern Methodist University. He is also a Certified Public Accountant and a member of the American Institute of Certified Public Accountants.
Robert Bujarski	Mr. Robert Joseph Bujarski, J.D., is Senior Vice President - Business Development, General Counsel, Corporate Secretary of Quidel Corp. He became Senior Vice President, General Counsel and Corporate Secretary in June 2008 and in 2010 became Senior Vice President, Business Development, General Counsel and Corporate Secretary. Mr. Bujarski previously served as Senior Vice President, General Counsel and Corporate Secretary from March 2007 through March 2008. From July 2005 to March 2007, he was General Counsel and Vice President. Mr. Bujarski was an associate attorney with the law firm of Gibson, Dunn & Crutcher LLP in its transactions practice group from October 2001 to July 2005. Mr. Bujarski received his B.A. degree in 1991 and his law degree in 2001 from the University of Arizona.
Scot McLeod	Mr. Scot M. McLeod is Senior Vice President - Operations of Quidel Corporation, since July 2007. Mr. McLeod previously served as the Company’s Vice President, Operations from 2001 to July 2007. Mr. McLeod first joined the Company in 1997 as Director of Production and has held various management operations positions with the Company throughout his 14 years of service. Mr. McLeod has over 20 years experience in operations and a diverse manufacturing background in both domestic and international environments. Mr. McLeod spent five years with an overseas manufacturer of computer peripherals. Prior to joining Quidel, Mr. McLeod held various positions in operations and quality with Medtronic Interventional Vascular, Hybritech Inc., ALCOA and Information Magnetics Corporation. Mr. McLeod has his B.S. in Chemical Engineering from the University of New Hampshire.
Mark Smits	Mr. Mark W. Smits is Senior Vice President - Commercial Operations of Quidel Corporation. From August 2010 to May 2011 Mr. Smits served as Vice President of Sales and Marketing for Neogenomics, a provider of cancer-focused testing laboratories. From October 2008 to August 2010, Mr. Smits was Vice President of Marketing and Business Development for Fisher HealthCare, Inc., a division of Thermo Fisher Scientific, Inc. which is a supplier of analytical instruments, laboratory equipment, software, services, consumables and reagents. Mr. Smits led the sourcing and business development efforts for Fisher HealthCare. Prior to Fisher HeatlthCare, Mr. Smits spent 25 years with Abbott Diagnostics, which offers instrument systems and tests for hospitals, reference labs, blood banks, physician offices, and clinics, serving in several different roles including, from October 2002 until September 2008, Divisional Vice President, Western United States Commercial Operations, where he led an organization of 250 people to provide sales, service and support to customers. Mr. Smits received his B.S. from Texas A&M University.
John Tamerius	Dr. John D. Tamerius, Ph.D., is Senior Vice President - Clinical, Regulatory Affairs of Quidel Corp. Dr. Tamerius previously served as the Company’s Vice President, Clinical/Regulatory Affairs from 2005 to November 2008. Dr. Tamerius has held a variety of positions with the company including, among others: Vice President for Research and Development and General Manager of the Company’s Special Products Group. Dr. Tamerius joined the Company in 1983 with the acquisition of Cytotech, Inc. where he served as President. Dr. Tamerius was previously a research associate at Scripps Clinic and Research Foundation. Dr. Tamerius performed postdoctoral research in tumor immunology at the Fred Hutchinson Cancer Center in Seattle and was awarded a Bachelor of Science, Master of Science, and Doctor of Philosophy in Microbiology and Immunology, all from the University of Washington.
Timothy Stenzel	Dr. Timothy Todd Stenzel, M.D., Ph.D., is Chief Scientific Officer of Quidel Corporation, since September 2009. Prior to joining the Company, Dr. Stenzel was Vice President and Chief Medical Officer since 2007 for Asuragen Inc (Austin, TX). Dr. Stenzel has also held senior positions at Abbott Laboratories from 2003 to 2007 and Duke University from 1997 to 2003, where he established Duke’s molecular laboratory capabilities. Dr. Stenzel received his M.D. and Ph.D. from Duke University and a B.A. in Chemistry from Grinnell College.
Thomas Brown	Mr. Thomas D. Brown is Independent Director of Quidel Corporation, since December 2004. Prior to his retirement in 2002, Mr. Brown had a 28-year career in the healthcare industry where he held various sales, marketing and executive positions within Abbott Laboratories, a broad-based healthcare company. From 1998 to 2002, Mr. Brown was Senior Vice President and President of the Diagnostics Division. From 1993 to 1998, Mr. Brown was Corporate Vice President Worldwide Commercial Operations. From 1992 to 1993, Mr. Brown was Divisional Vice President Worldwide Commercial Operations. From 1987 to 1992, Mr. Brown was Divisional Vice President and General Manager, Western Hemisphere Commercial Operations. From 1986 to 1987, Mr. Brown was Divisional Vice President U.S. Sales and, from 1985 to 1986, was Director of Sales. Mr. Brown currently serves on the Board of Directors of Cepheid, a molecular diagnostics company, and Stericycle, Inc., a medical waste management and healthcare compliance services company. Mr. Brown also served on the Board of Directors of Ventana Medical Systems, Inc. until its acquisition in 2008. Mr. Brown holds a Bachelor of Arts degree from the State University of New York at Buffalo.
Kenneth Buechler	Dr. Kenneth F. Buechler, Ph.D., is Independent Director of Quidel Corporation, since November 2007. Dr. Buechler was a founder of Biosite, Inc., a diagnostic products and antibody development company. Dr. Buechler served as a Director at Biosite from June 2003 through July 2007 and was President and Chief Scientific Officer of Biosite from October 2004 to July 2007. From March 2003 to October 2004, Dr. Buechler was Biosite’s Senior Vice President, Research and Development, and from April 2001 to March 2003, Dr. Buechler was Biosite’s Vice President, Research and Development. From January 1994 to April 2001, Dr. Buechler was Biosite’s Vice President, Research and was Director of Chemistry from April 1988 to January 1994. Before founding Biosite, Dr. Buechler was a Senior Scientist in the Diagnostics Research and Development Group at Hybritech Incorporated. Dr. Buechler received a B.S. in Chemistry and Ph.D. in Biochemistry from Indiana University. Dr. Buechler also serves on the Board of Directors of Sequenom Inc., Sotera Wireless Inc. and Astute Medical Inc.
Rodney Dammeyer	Mr. Rodney F. Dammeyer is Independent Director of Quidel Corporation, since February 2006. Mr. Dammeyer is the President of CAC, L.L.C., a private company providing capital investment and management advisory services, and is the retired Vice Chairman of Anixter International, where he served from 1985 until February 2001, and retired managing partner of corporate investments of Equity Group Investments, L.L.C., where he served from 1995 until June 2000. Mr. Dammeyer currently serves as a director of Stericycle, Inc., a medical waste management and healthcare compliance services company. Mr. Dammeyer has also served on the Board of Directors of Ventana Medical Systems, Inc. and GATX Corporation within the past five years. He also serves as a trustee of Van Kampen Investments, Inc. and as an independent trustee of various Invesco Van Kampen mutual funds. He received a B.S. degree in accounting from Kent State University.
Mary Polan	Dr. Mary Lake Polan, M.D., Ph.D., is Independent Director of Quidel Corporation, since 1993. She is a Professor and Chair Emerita of the Department of Gynecology and Obstetrics at Stanford University School of Medicine where she served from 1990 to 2005. Dr. Polan received a Bachelor of Arts Degree from Connecticut College, a Ph.D. in Molecular Biophysics and Biochemistry and an M.D. from Yale University School of Medicine and her Masters in Public Health from the University of California, Berkeley. Dr. Polan remained at Yale New Haven Hospital for her residency in Obstetrics and Gynecology, followed by a Reproductive Endocrine Fellowship. Dr. Polan was on the faculty at Yale University until 1990, when she joined Stanford University. She is currently an Adjunct Professor in the Department of Obstetrics and Gynecology at Columbia University School of Medicine. Dr. Polan is a practicing clinical Reproductive Endocrinologist with a research interest in ovarian function and granulosa cell steroidogenesis. More recently, Dr. Polan’s interests have been in the interaction between the immune and endocrine systems: the role of monokines in reproductive events and gene expression in stress urinary incontinence as well as brain activation in human sexual function. Dr. Polan also served on the Board of Directors of Wyeth, a research-based global pharmaceutical and health care products company, until its acquisition in 2009.
Jack Schuler	Mr. Jack W. Schuler is Independent Director of Quidel Corporation, since February 2006. Mr. Schuler has been on the Board of Directors of Stericycle, Inc., a medical waste management and healthcare compliance services company, since March 1989 and currently serves as Lead Director. Mr. Schuler is also a co-founder of Crabtree Partners, LLC, a Chicago-based venture capital firm which was formed in 1995. Prior to 1990, Mr. Schuler held various executive positions at Abbott Laboratories, a broad-based healthcare company, from December 1972 through August 1989, most recently serving as President and Chief Operating Officer. Mr. Schuler also currently serves on the Board of Directors of Medtronic Inc. Mr. Schuler also served on the Board of Directors of Ventana Medical Systems, Inc. within the last five years. Mr. Schuler holds a B.S. in Mechanical Engineering from Tufts University and an M.B.A. from Stanford University.

Basic Compensation

Name	Fiscal Year Total
Mark Pulido	--
Douglas Bryant	1,650,090
Randall Steward	606,417
Robert Bujarski	720,430
Scot McLeod	630,126
Mark Smits	--
John Tamerius	708,510
Timothy Stenzel	693,754
Thomas Brown	--
Kenneth Buechler	--
Rodney Dammeyer	--
Mary Polan	--
Jack Schuler	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Mark Pulido	0	0
Douglas Bryant	0	0
Randall Steward	0	0
Robert Bujarski	123,624	814,814
Scot McLeod	12,827	103,450
Mark Smits	0	0
John Tamerius	199,125	225,418
Timothy Stenzel	0	0
Thomas Brown	0	0
Kenneth Buechler	0	0
Rodney Dammeyer	0	0
Mary Polan	0	0
Jack Schuler	0	0

Insider Trading

Name	Shares Traded	Price
BUJARSKI ROBERT JOSEPH	19,196	$23.02
BUJARSKI ROBERT JOSEPH	8,283	$23.35
BUECHLER KENNETH F	2,600	$0.00
DAMMEYER RODNEY F	2,600	$0.00
POLAN MARY LAKE	2,600	$0.00
BROWN THOMAS D	2,600	$0.00
PULIDO MARK A	3,413	$0.00
BUECHLER KENNETH F	434	$0.00
DAMMEYER RODNEY F	642	$0.00
BUECHLER KENNETH F	2,172	$0.00
DAMMEYER RODNEY F	3,212	$0.00
BUJARSKI ROBERT JOSEPH	3,181	$22.60
TAMERIUS JOHN D	11,719	$7.50
TAMERIUS JOHN D	17,133	$8.50
BRYANT DOUGLAS C	13,331	$22.70
TAMERIUS JOHN D	943	$21.36
BRYANT DOUGLAS C	3,681	$21.36
MCLEOD SCOT M	927	$21.36
STENZEL TIMOTHY TODD	1,022	$21.36
BUJARSKI ROBERT JOSEPH	1,151	$21.36
TAMERIUS JOHN D	9,000	$3.19
POLAN MARY LAKE	18,000	$0.00
POLAN MARY LAKE	9,331	$9.93
POLAN MARY LAKE	4,081	$0.00
POLAN MARY LAKE	12,750	$5.44

» Full list on Insider Trading

People: Quidel Corp (QDEL.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: